1. Doubling 2-Year Survival Rate: Glioblastoma Multiforme

Glioblastoma (GBM) is the most aggressive brain cancer . A randomized Phase I/II clinical trial [1] showed that the addition of Hyperthermia to brachytherapy, after conventional radiotherapy, had a dramatic impact on the prognosis of cancer patients, * doubling the 2-year survival rate *:

A relative increase of *over 100%* in the survival of cancer patients at 2 years is convincing evidence of the power of Hyperthermia as an adjuvant cancer treatment .

More recent meta-analyses [2] confirm similar benefits of modulated RF hyperthermia mHT in newly diagnosed disease, with a 1-year Survival rate of *73%* versus *37%* in the control arm (recurrent disease) (p = 0.0021).

Strong survival signals from comparative studies, even in the difficult clinical setting of gliomas, justify the inclusion of HT as a Level 1A indication in clinical guidelines.

2. Extending Survival Type: Increasing OS by Over 50% in Pancreatic Cancer

Pancreatic Cancer (PC) has one of the worst prognoses. Consolidated clinical evidence shows that Hyperthermia significantly modifies the clinical trajectory, consistently demonstrating an increase in OS survival of oncological patients by over 50%:

1. * Adjuvant HEAT Randomized Clinical Trial (2022) [3]:* In resected pancreatic cancer, the addition of Regional Hyperthermia (RHT) resulted in 5-year survival rates of *28.4% versus 18.7%* ( a relative increase in survival of *52%* ).
2. * Comparative Integrative Study (2023) [4]: ​​* In metastatic pancreatic cancer, integrative immunomodulatory treatment (including modulated RF hyperthermia mHT) was *significantly superior* to conventional chemotherapy

   

3.  A large retrospective observational multicenter study [5] (N=217 patients with stage III-IV PC) compared RF-modulated hyperthermia mHT + CT chemotherapy (mainly based on gemcitabine) with CT alone.
   ● Overall Survival (OS): OS was significantly improved (more than DOUBLE) in the RF-modulated hyperthermia mHT group (20 months, vs. 9 months in the CT group, P < 0.001).
   ● Progression-Free Survival (PFS): PFS was also significantly improved (7 months, vs. 5 months, P < 0.05).
   ● Tumor Response: Patients treated with local RF-hyperthermia mHT had a significantly higher Partial Response Rate (PR) (45% vs. 24%, P = 0.0018) and a substantially lower progression (PD) rate (4% vs. 31%, P < 0.01).

3. Long-Term Phase III Evidence: Soft Tissue Sarcoma (EORTC 62961)

In a multi-national phase III randomized clinical trial (RCT),the gold standard, * EORTC 62961/ESHO 95 * [5] , patients who underwent CT NA for STS, the median overall OS survival was more than DOUBLED , with minimal toxicities , leading to the inclusion of HT in both the NCCN and ESMO guidelines.

The study was initiated by the European Society of Hyperthermic Oncology (ESHO) and coordinated by the Klinikum der Universität München, Munich, Germany, in collaboration with the Soft Tissue Sarcoma of Bone Group (STBSG) of the European Organization for Research and Treatment of Cancer (EORTC). Participating academic centers were in Germany (6), Norway (1), Austria (1), and the United States (1).

Adult patients (aged ≥18 years) with localized soft tissue sarcoma (tumor ≥5 cm, grade 2 or 3, deep, according to the French National Federation of Cancer Control Centers [FNCLCC]) were enrolled in the 9 centers from July 1997 to November 2006. Follow-up ended in December 2014.

The addition of regional hyperthermia RHT prolonged the median disease-free survival from 17.4 months to 33.3 months (HR for local or distant failure or death, 0.71; 95% CI, 0.55–0.93; P   = 0.01;  Figure 2B  ).

Survival between the study groups was significantly improved in the NACT plus RHT group, with a median duration of 15.4 years compared with 6.2 years in the NACT-alone group (HR 0.73; 95% CI, 0.54-0.98; P = .04; Figure 2C).

Survival rates at 5-years and 10 years were 62.7% (95% CI, 55.2%-70.1%) and 52.6% (95% CI, 44.7%-60.6%), respectively, in the NACT plus RHT group, and 51.3% (95% CI, 43.7%-59.0%) and 42.7% (95% CI, 35.0%-50.4%), respectively, in the NACT-alone group. The number of patients needed to treat to achieve the survival benefit at 5 years and 10 years were 8.8 and 10.1, respectively. By post hoc analyses, in patients with extremity tumors survival rates at 5 years and 10 years in favor of RHT were 75.2% vs 60.8% (absolute difference, 14.4%; 95% CI, 0.0%-29.5%), and 68.3% vs 59.2% (absolute difference, 9.1%; 95% CI, 0%-24.7%), respectively. In patients with nonextremity survival rates at 5 years and 10 years in favor of RHT were 53.5% vs 44% (absolute difference, 9.5%; 95% CI, 0%-23.8%) and 41.3% vs 29.9% (absolute difference, 11.4%; 95% CI 0%-25.1%), respectively (Figure 2D). The summary of treatment outcomes is provided in eTable 1 in Supplement 2.

Survival was significantly improved by adding regional hyperthermia to neoadjuvant chemotherapy, with an absolute difference at 5 years of 11.4% and at 10 years of 9.9%, compared with neoadjuvant chemotherapy administered as monotherapy.

4. Level 1A Evidence from Phase III Clinical Trials: Improvement in Complete Response (CR) and Survival (OS)

• * Cervical Cancer (12-Year Follow-up) [7]:* The Dutch Deep Hyperthermia Clinical Trial (Phase III), updated at 12 years of follow-up, demonstrated a major improvement in Overall Survival (OS): *37%* in the RT+HT group versus *20%* in the RT alone group .
• * Breast Cancer Recurrence (Chest Wall) :*Meta-analysis[8] demonstrated a relative increase of *+58%* in the Complete Response Rate (CR) with the addition of HT to re-irradiation.  In the 2-arm studies, a complete response CR of 60.2% was achieved with RT + HT versus 38.1% with RT alone  (odds ratio 2.64, 95% confidence interval [CI] 1.66-4.18, P  <0.0001). The hazard ratio and risk difference were 1.57 (95% CI 1.25-1.96,  P  <.0001) and 0.22 (95% CI 0.11-0.33,  P  <.0001), respectively.
• * Rectal Cancer (Advanced/Recurrent)[9]: * After a 5-year follow-up, the overall survival rates OS (95.8 vs. 74.5%, P  = 0.045), disease-free survival DFS ( 89.1 vs. 70.4% , P  = 0.027), local recurrence-free survival ( 97.7 vs. 78.7% , P  = 0.006), and colostomy-free survival ( 87.7 vs. 69.0% , P  = 0.016) were significantly better for the group of cancer patients with hyperthermia added to the treatment.
• * Head and Neck Cancer (HNC): Randomized Phase III trials showed a consistent increase in 5-year OS from 50% to 68.4% (p < 0.005). 5-year Disease-Free Survival (DFS) increased from 25.5% to 51.3% (p < 0.005). CR rate also increased from 62.8% to 81.6% . In another phase III trial[10], complete CR was observed in 42.4% of the radiotherapy-only group compared to 78.6% in the HT group . The difference was statistically significant (< 0.05).
• * High-Risk Melanoma (EORTC 18951/ESHO 1.96) :* A Phase II/III clinical trial[11] demonstrated that Regional Hyperthermia in combination with chemotherapy significantly improves Overall Survival also in patients with advanced melanoma:
  • 5-year Overall Survival: The overall rate was 19%.
  • 5-year survival for patients with completely controlled disease: Increased to 38% .
  • Local Actuarial Control at 2 Years 28% VS 46% in the HT group Significant improvement (p = 0.008)
• Bladder Cancer (Non-Invasive) Bladder cancer is among the Level 1A indications for the addition of hyperthermia to oncology treatment.[12] Hyperthermic Intravesical Chemotherapy (HIVEC) combined with Mitomycin C is a well-established method that shows a significant improvement in Recurrence Rate:

  • Reduction of Recurrence: In intermediate- and high-risk non-invasive bladder cancer, HIVEC has been shown to be superior to standard room-temperature chemotherapy instillations.
  • Consolidated Results: Meta-analyses and clinical trials (including randomized trials) have reported a reduction in the risk of recurrence of over 30% compared with standard intravesical chemotherapy in intermediate- and high-risk patients [12]
  • Efficacy in BCG Failure: HIVEC is an essential option for patients in whom standard BCG (Bacillus Calmette-Guérin) therapy has failed or is contraindicated, improving recurrence-free survival (RFS) rates.

5. Safety and Favorable Therapeutic Index (Toxicity)

A crucial aspect of the Phase III evidence is that the massive survival benefit is achieved without significantly increasing severe Grade 3 or 4 toxicity. Meta-analyses in Cervical Cancer, for example, observed *no significant difference* in acute or late toxicity (RR 0.99 for acute toxicity, RR 1.01 for late toxicity).

This observation holds true in other indications, reinforcing the argument that HT offers a superior therapeutic index, allowing patients to better tolerate complex regimens and have improved *Quality of Life* in the long term.

Conclusion: A Validated Therapeutic Survival Strategy

Whether it's a 52% increase in OS (Pancreatic Cancer), a +17 percentage point increase at 12 years (Cervical Cancer) or a Doubling of survival time (Glioblastoma and Soft Tissue Sarcoma ) , evidence from randomized trials confirms that Hyperthermia is not just an adjuvant treatment, but an essential component that positively alters the trajectory of *Overall Survival* for oncology patients.

*If your goal is to maximize Overall Survival, integrating Hyperthermia into the standard protocol is a scientifically validated decision, with results exceeding 50% relative increase in some indications.*